CDH5 and hepatoblastoma: In the study of Zhang and colleagues, low dosages of ATO decreased the formation of vasculogenic mimicry (VM) in hepatoblastoma cells in vitro and in vivo via reducing the expression levels of VM-associated proteins such as VE-cadherin and MMP-9 [31].